IONS Q1 2022 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$142M+27.2% YoY

Gross Profit

$138M97.1% margin

Operating Income

-$58M-40.5% margin

Net Income

-$65M-45.9% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

-67.7%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$35M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$1.8B

Stockholders' Equity

$710M

Cash & Equivalents

$543M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$142M	$112M	+27.2%
Gross Profit	$138M	$109M	+26.3%
Operating Income	-$58M	-$92M	+37.5%
Net Income	-$65M	-$90M	+27.5%

Revenue Segments

Commercial

$72M25%

Research and Development Revenue

$70M25%

Spinraza Royalties

$54M19%

Collaborative Agreement Revenue

$50M18%

Eplontersen Joint Development Revenue

$20M7%

Licensing and Other Royalties

$12M4%

Product

$6M2%